SGLT2 inhibitors improves cardiovascular outcomes across a broad range of heart and kidney conditions
A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD). Findings were presented at the American College of Cardiology Annual Scientific Session & Expo and simultaneously published […]
SMART-C launches institutional GitHub organisation
SMART-C has recently launched its own GitHub organisation. This organisation will serve as a platform for code repositories that promote open access principles and scientific collaboration in clinical trials research. The aim of this initiative is to enhance transparency, reproducibility, and streamline analyses led by the Consortium. GitHub, a widely recognised platform used predominantly by […]
SGLT2 inhibitors offer clear and powerful protection against kidney disease progression in people with and without diabetes
A landmark meta-analysis conducted by the Nuffield Department of Population Health and the SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium (SMART-C), published in The Lancet, has demonstrated the SGLT2 inhibitors have clear and powerful effects on reducing kidney disease progression, regardless of diabetes. The study entitled “Impact of diabetes on the effects of sodium glucose co-transporter-2 […]
